The SARS-CoV-2 vaccine and enrollment of patients with cancer in phase I trials: the experience at Institute Gustave Roussy
Annals of Oncology
; 33(Suppl. 1):S18-S18, 2022.
Article
in English
| GIM | ID: covidwho-1971952
ABSTRACT
Background:
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with a disruption of all components of cancer care from screening, diagnosis, surveillance, treatment and clinical trial enrollment. Patients with cancer are considered a priority for SARS-CoV-2 vaccination. However, no data are available regarding patients with cancer enrolled in phase I trials and vaccination status.
human diseases; patients; coronavirus disease 2019; viral diseases; vaccination; risk factors; clinical aspects; immunization; respiratory diseases; vaccines; disease prevention; health protection; neoplasms; outbreaks; clinical trials; retrospective studies; reviews; risk; lungs; embolism; safety; cytokines; immune sensitization; man; Severe acute respiratory syndrome coronavirus 2; France; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; European Union Countries; high income countries; Mediterranean Region; OECD Countries; very high Human Development Index countries; Western Europe; Europe; SARS-CoV-2; viral infections; clinical picture; lung diseases; cancers
Full text:
Available
Collection:
Databases of international organizations
Database:
GIM
Topics:
Vaccines
Language:
English
Journal:
Annals of Oncology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS